《KDOQI慢性肾脏病营养临床实践威廉亚洲博彩公司 2020更新版》解读

2021-02-08 四川大学华西医院临床营养科 中国全科医学 发表于安徽省

更新威廉亚洲博彩公司 内容涵盖6个领域:营养评估、医学营养治疗、膳食蛋白质和能量摄入、营养补充剂、微量营养素和电解质。主要包括饮食管理,而不是所有可能的营养干预。

中文标题:

《KDOQI慢性肾脏病营养临床实践威廉亚洲博彩公司 2020更新版》解读

发布日期:

2021-02-08

简要介绍:

2020年9月,国家肾脏基金会肾病预后质量倡议(KDOQI)发布《KDOQI 慢性肾病营养临床实践威廉亚洲博彩公司 2020更新版》。20年前KDOQI发布首个终末期肾病患者营养威廉亚洲博彩公司 ,20年来营养管理的新证据不断出现。更新威廉亚洲博彩公司 不仅包括终末期肾病或晚期慢性肾脏病(CKD)患者,还包括未接受透析的1~5期CKD患者和肾移植患者。更新威廉亚洲博彩公司 内容涵盖6个领域:营养评估、医学营养治疗、膳食蛋白质和能量摄入、营养补充剂、微量营养素和电解质。主要包括饮食管理,而不是所有可能的营养干预。本文对其中主要内容进行解读,并结合我国实际情况进行讨论。

相关资料下载:
[AttachmentFileName(sort=1, fileName=《KDOQI慢性肾脏病营养临床实践威廉亚洲博彩公司 2020更新版》解读.pdf)] GetToolGuiderByIdResponse(projectId=1, id=d8a521c0029a8ef5, title=《KDOQI慢性肾脏病营养临床实践威廉亚洲博彩公司 2020更新版》解读, enTitle=, guiderFrom=中国全科医学, authorId=0, author=, summary=更新威廉亚洲博彩公司 内容涵盖6个领域:营养评估、医学营养治疗、膳食蛋白质和能量摄入、营养补充剂、微量营养素和电解质。主要包括饮食管理,而不是所有可能的营养干预。, cover=https://img.medsci.cn/20221109/1668021798780_4754896.webp, journalId=0, articlesId=null, associationId=4050, associationName=四川大学华西医院临床营养科, associationIntro=四川大学华西医院临床营养科, copyright=0, guiderPublishedTime=Mon Feb 08 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span class="fontstyle0">2020年9月,国家肾脏基金会肾病预后质量倡议(KDOQI)发布《KDOQI 慢性肾病营养临床实践威廉亚洲博彩公司 2020更新版》。20年前KDOQI发布首个终末期肾病患者营养威廉亚洲博彩公司 ,20年来营养管理的新证据不断出现。更新威廉亚洲博彩公司 不仅包括终末期肾病或晚期慢性肾脏病(CKD)患者,还包括未接受透析的1~5期CKD患者和肾移植患者。更新威廉亚洲博彩公司 内容涵盖6个领域:营养评估、医学营养治疗、膳食蛋白质和能量摄入、营养补充剂、微量营养素和电解质。主要包括饮食管理,而不是所有可能的营养干预。本文对其中主要内容进行解读,并结合我国实际情况进行讨论。</span></p>, tagList=[TagDto(tagId=1821, tagName=营养), TagDto(tagId=2551, tagName=慢性肾病)], categoryList=[CategoryDto(categoryId=14, categoryName=肾内科, tenant=100), CategoryDto(categoryId=85, categoryName=威廉亚洲博彩公司 &解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=2527, articleKeyword=慢性肾脏病, articleKeywordNum=6, guiderKeywordId=2527, guiderKeyword=慢性肾脏病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=解读, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2140, appHits=126, showAppHits=0, pcHits=299, showPcHits=2014, likes=2, shares=15, comments=7, approvalStatus=1, publishedTime=Thu Feb 02 13:21:00 CST 2023, publishedTimeString=2021-02-08, pcVisible=1, appVisible=1, editorId=0, editor=QIAN LIN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=5, createdBy=null, createdName=QIAN LIN, createdTime=Mon Jan 30 22:25:43 CST 2023, updatedBy=2427819, updatedName=梁丽玲, updatedTime=Sat Jan 06 00:22:35 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=安徽省, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=《KDOQI慢性肾脏病营养临床实践威廉亚洲博彩公司 2020更新版》解读.pdf)])
《KDOQI慢性肾脏病营养临床实践威廉亚洲博彩公司 2020更新版》解读.pdf
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2215683, encodeId=b2a3221568303, content=学习了,很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9c58658087, createdName=ms1000001713362997, createdTime=Thu Jul 18 23:23:24 CST 2024, time=2024-07-18, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2214331, encodeId=9ff22214331ad, content=很棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b958459617, createdName=ms1000001318479649, createdTime=Wed Jul 10 22:56:25 CST 2024, time=2024-07-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2214330, encodeId=3edd2214330c9, content=干货!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b958459617, createdName=ms1000001318479649, createdTime=Wed Jul 10 22:56:11 CST 2024, time=2024-07-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2157499, encodeId=4cfe215e499db, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20375727516, createdName=ms5000000109506424, createdTime=Wed Sep 13 11:13:10 CST 2023, time=2023-09-13, status=1, ipAttribution=四川省)]
    2024-07-18 ms1000001713362997 来自福建省

    学习了,很实用

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2215683, encodeId=b2a3221568303, content=学习了,很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9c58658087, createdName=ms1000001713362997, createdTime=Thu Jul 18 23:23:24 CST 2024, time=2024-07-18, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2214331, encodeId=9ff22214331ad, content=很棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b958459617, createdName=ms1000001318479649, createdTime=Wed Jul 10 22:56:25 CST 2024, time=2024-07-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2214330, encodeId=3edd2214330c9, content=干货!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b958459617, createdName=ms1000001318479649, createdTime=Wed Jul 10 22:56:11 CST 2024, time=2024-07-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2157499, encodeId=4cfe215e499db, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20375727516, createdName=ms5000000109506424, createdTime=Wed Sep 13 11:13:10 CST 2023, time=2023-09-13, status=1, ipAttribution=四川省)]
    2024-07-10 ms1000001318479649 来自广东省

    很棒

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2215683, encodeId=b2a3221568303, content=学习了,很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9c58658087, createdName=ms1000001713362997, createdTime=Thu Jul 18 23:23:24 CST 2024, time=2024-07-18, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2214331, encodeId=9ff22214331ad, content=很棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b958459617, createdName=ms1000001318479649, createdTime=Wed Jul 10 22:56:25 CST 2024, time=2024-07-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2214330, encodeId=3edd2214330c9, content=干货!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b958459617, createdName=ms1000001318479649, createdTime=Wed Jul 10 22:56:11 CST 2024, time=2024-07-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2157499, encodeId=4cfe215e499db, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20375727516, createdName=ms5000000109506424, createdTime=Wed Sep 13 11:13:10 CST 2023, time=2023-09-13, status=1, ipAttribution=四川省)]
    2024-07-10 ms1000001318479649 来自广东省

    干货!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2215683, encodeId=b2a3221568303, content=学习了,很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9c58658087, createdName=ms1000001713362997, createdTime=Thu Jul 18 23:23:24 CST 2024, time=2024-07-18, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2214331, encodeId=9ff22214331ad, content=很棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b958459617, createdName=ms1000001318479649, createdTime=Wed Jul 10 22:56:25 CST 2024, time=2024-07-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2214330, encodeId=3edd2214330c9, content=干货!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b958459617, createdName=ms1000001318479649, createdTime=Wed Jul 10 22:56:11 CST 2024, time=2024-07-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2157499, encodeId=4cfe215e499db, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20375727516, createdName=ms5000000109506424, createdTime=Wed Sep 13 11:13:10 CST 2023, time=2023-09-13, status=1, ipAttribution=四川省)]
    2023-09-13 ms5000000109506424 来自四川省

    点赞

    0

拓展阅读

陈香美院士/蔡广研/欧阳清/李莉莉合作《CMI》:利用体内自组装多肽调控促纤维化巨噬细胞抑制肾脏纤维化进展

研究确定促纤维化巨噬细胞亚群,构建自组装多肽,通过重塑免疫微环境抑制肾脏纤维化,为慢性肾脏病治疗提供潜在方法。

Nat Rev Nephrol:人口老龄化对慢性肾脏病负担的影响

随着全球人口迅速老龄化,预计到2050年,慢性肾病(CKD)患病率将显著增加,特别是在低收入国家,增加预防、早期检测和药物可及性将是应对这一挑战的关键。

赵景宏/黄英辉/顾军团队《AHM》:自组装P38肽抑制剂纳米颗粒(TMNPs)通过抑制铁死亡改善AKI向CKD的转变

该研究设计开发了一种新型自组装P38肽抑制剂纳米颗粒,通过协同性地清除活性氧和激活SLC7A11/GPX4信号通路而抑制肾小管上皮细胞铁死亡,从而改善 AKI 及其向 CKD 的转变。

2024年威廉亚洲博彩公司 :肾病9大食养建议,这样吃喝…更合理

关注慢性肾脏病患者营养问题,并将营养治疗贯穿于整个慢性肾脏病治疗过程,对于提高疾病整体诊治水平、延缓疾病进展、改善患者预后等具有重要意义。

LANCET:Zibotentan联合达格列净与达格列净联合安慰剂治疗慢性肾脏病疗效的比较(ZENITH-CKD研究)

zibotentan联合达格列净可降低白蛋白尿,且耐受性和安全性均可接受,有望成为慢性肾病患者的一种全新治疗选择。

PNAS:近端小管视黄酸受体α的活性可预防肾损伤和纤维化

未来,仍需要进一步的研究来确定RARα如何维持PT稳态,以及导致性别差异的根本原因。

2015慢性肾脏病评估及管理临床实践威廉亚洲博彩公司 解读——从 K/DOQI 到 KDIGO

国际肾脏病学会(ISN,International Society of Nephrology) · 2016-04-25

慢性肾脏病筛查诊断及防治威廉亚洲博彩公司

肾脏病相关专家小组(统称) · 2017-01-30

HIV感染合并慢性肾脏病患者管理专家共识

中国感染病相关专家组(统称) · 2017-06-15